Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.53 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | LCK | P06239 | 1/20 | 0.52 |
| ▸ | PPARD | Q03181 | 1/20 | 0.52 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.52 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.52 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.44 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9386007 | 1.00 | GPR84 (0.53) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL22129540 | 1.00 | GPR84 (0.53) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL4668834 | 1.00 | GPR84 (0.53) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL571167 | 1.00 | GPR84 (0.53) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL18040465 | 1.00 | GPR84 (0.53) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL450317 | 1.00 | GPR84 (0.53) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL270550 | 1.00 | GPR84 (0.53) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL20560019 | 1.00 | GPR84 (0.53) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL2269027 | 0.96 | CA2 (0.50) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL20563203 | 0.94 | GPR84 (0.52) | GPR84FFAR1MAPTLCKPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3687497-B1 | TOPICAL COMPOSITION AND METHOD FOR TREATING AND PREVENTING ATOPIC DERMATITIS AND INFECTIONS RELATED TO BACTERIA BIOFILM | JOHNSON & JOHNSON CONSUMER INC (US) | 2023-06-28 | — | — | EP | claimed |
| EP-3113847-B1 | ANHYDROUS DYEING COMPOSITION AND PROCESS FOR DYEING HAIR | KAO GERMANY GMBH (DE) | 2019-11-20 | — | — | EP | claimed |
| EP-3113848-B1 | ANHYDROUS DYEING COMPOSITION AND PROCESS FOR DYEING HAIR | KAO GERMANY GMBH (DE) | 2018-10-31 | — | — | EP | claimed |
| WO-2025103640-A1 | ACTIVE INGREDIENT COMBINATIONS CONSISTING OF ALKYLAMIDOTHIAZOLES AND OIL COMPONENTS | BEIERSDORF AG (DE) | 2025-05-22 | — | — | WO | disclosed |
| EP-4213627-A1 | STABILIZATION OF THIOKETONES ON SURFACES | Bayer Aktiengesellschaft (DE) | 2023-07-26 | — | — | EP | disclosed |
| WO-2022058522-A1 | STABILIZATION OF THIOKETONES ON SURFACES | BAYER AKTIENGESELLSCHAFT (DE) | 2022-03-24 | — | — | WO | disclosed |
| EP-3941199-A1 | STABILIZED THIOKETONE FORMULATIONS | Bayer Aktiengesellschaft (DE) | 2022-01-26 | — | — | EP | disclosed |
| CN-112996474-A | Oil-in-water skin care cosmetic composition containing oil gelling agent | 株式会社爱茉莉太平洋 | 2021-06-18 | — | — | CN | disclosed |
| WO-2020187871-A1 | STABILIZED THIOKETONE FORMULATIONS | BAYER AKTIENGESELLSCHAFT (DE) | 2020-09-24 | — | — | WO | disclosed |
| US-10744138-B2 | Combined hair loss inhibition treatment | GARUHDA LLC (US) | 2020-08-18 | — | — | US | disclosed |
| EP-3638034-A1 | STABILISED FORMULATIONS CONTAINING PROTHIOCONAZOLE WITH A LOW 2-(1-CHLOROCYCLOPROPYL)-1-(2-CHLOROPHENYL)-3-(1H-1,2,4-TRIAZOL-1-YL)PROPAN-2-OL CONTENT | Bayer Aktiengesellschaft (DE) | 2020-04-22 | — | — | EP | disclosed |
| EP-2883534-A1 | Warming 2-component oil hair treatment | Henkel AG & Co. KGaA (DE) | 2015-06-17 | — | — | EP | disclosed |
| EP-2582348-A2 | TWO-PHASE DEVELOPER | Henkel AG & Co. KGaA (DE) | 2013-04-24 | — | — | EP | disclosed |
| EP-2563321-A2 | COLORANTS FOR KERATINIC FIBRES HAVING OPTIMIZED VISCOSITY ADJUSTMENT | Henkel AG & Co. KGaA (DE) | 2013-03-06 | — | — | EP | disclosed |
| EP-2550066-A2 | VISCOSITY-PRODUCING TWO PHASE DEVELOPER WITH A CLEAR OIL PHASE FOR OXIDATIVE COLOUR MODIFYING AGENTS | Henkel AG & Co. KGaA (DE) | 2013-01-30 | — | — | EP | disclosed |
| WO-2011117004-A2 | VISCOSITY-PRODUCING TWO PHASE DEVELOPER WITH A CLEAR OIL PHASE FOR OXIDATIVE COLOUR MODIFYING AGENTS | HENKEL AG & CO. KGAA (DE) | 2011-09-29 | — | — | WO | disclosed |
| WO-2011116844-A2 | COLORANTS FOR KERATINIC FIBRES HAVING OPTIMIZED VISCOSITY ADJUSTMENT | HENKEL AG & CO. KGAA (DE) | 2011-09-29 | — | — | WO | disclosed |
| WO-2011082910-A2 | TWO-PHASE DEVELOPER | HENKEL AG & CO. KGAA (DE) | 2011-07-14 | — | — | WO | disclosed |
| CN-100537685-C | Concrete surface retarders | GRACE W R & CO (US) | 2009-09-09 | — | — | CN | disclosed |
| CN-1871320-A | Concrete surface retarders | GRACE W R & CO (US) | 2006-11-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10744138-B2 | Combined hair loss inhibition treatment | ATRIP, AP1M1, ACVRL1 | GPR84 4274/4885FFAR1 1484/4885MAPT 1757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.